Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + azacitidine in newly diagnosed AML
NCT06389292Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jun 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Ascentage Pharma. Started Jun 2024; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06389292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389292.